Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.

doi:10.1038/s41467-023-43175-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.

Nature communications - 25 Nov 2023

Fang Zijian, Corbizi Fattori Giuditta, McKerrell Thomas, Boucher Rebecca H, Jackson Aimee, Fletcher Rachel S, Forte Dorian, Martin Jose-Ezequiel, Fox Sonia, Roberts James, Glover Rachel, Harris Erica, Bridges Hannah R, Grassi Luigi, Rodriguez-Meira Alba, Mead Adam J, Knapper Steven, Ewing Joanne, Butt Nauman M, Jain Manish, Francis Sebastian, Clark Fiona J, Coppell Jason, McMullin Mary F, Wadelin Frances, Narayanan Srinivasan, Milojkovic Dragana, Drummond Mark W, Sekhar Mallika, ElDaly Hesham, Hirst Judy, Paramor Maike, Baxter E Joanna, Godfrey Anna L, Harrison Claire N, Méndez-Ferrer Simón

Abstract excerpt

Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen's safety and activity in patients with stable MPNs, no prior thrombotic events and mutated JAK2V617F, CALRins5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cells

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Neoplasms

Share to Signal Transduction

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 38001082
DOI: 10.1038/s41467-023-43175-5
PMCID: PMC10673935

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.PMID 38001082Read ↗

Tamoxifen reduces mitochondrial respiration, oncogenic signaling and mutant allele burden in a myeloproliferative neoplasm subsetSemantic proximity Read ↗

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.Semantic proximity Read ↗

Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis.Semantic proximity Read ↗

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.Semantic proximity Read ↗

Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapiesSemantic proximity Read ↗

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.Semantic proximity Read ↗

[The cutting edge of medicine: pathophysiology and treatment of myeloproliferative neoplasms].Semantic proximity Read ↗

Biology and Current Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.